Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players
- 1 March 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (5), 1284-1285
- https://doi.org/10.1158/1078-0432.ccr-07-2247
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- HMGA1 Is a Molecular Determinant of Chemoresistance to Gemcitabine in Pancreatic AdenocarcinomaClinical Cancer Research, 2008
- Distinct Populations of Cancer Stem Cells Determine Tumor Growth and Metastatic Activity in Human Pancreatic CancerCell Stem Cell, 2007
- Src, chemoresistance and epithelial to mesenchymal transition: are they related?Anti-Cancer Drugs, 2007
- Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cellsBritish Journal of Cancer, 2007
- Lentivirus-Mediated RNA Interference of HMGA1 Promotes Chemosensitivity to Gemcitabine in Pancreatic AdenocarcinomaJournal of Gastrointestinal Surgery, 2006
- Determination of High Mobility Group A1 (HMGA1) Expression in Hepatocellular Carcinoma: A Potential Prognostic MarkerDigestive Diseases and Sciences, 2005
- RNA Interference Demonstrates a Novel Role for Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine ChemoresistanceClinical Cancer Research, 2005
- Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancerSurgery, 2004
- siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivityJournal of the American College of Surgeons, 2004
- Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cellsSurgery, 2004